natgillin/translations-raw huggingface dataset:
The use of Komboglyze or saxagliptin has not been studied in pregnant women.
Uporaba zdravila Komboglyze ali saksagliptina pri nosečnicah ni raziskana.
So it is important to keep following the advice about diet and exercise from your doctor or nurse.
Zato je pomembno, da še naprej upoštevate navodila za dieto in telesno dejavnost, ki ste jih dobili od zdravnika ali medicinske sestre.
The time for saxagliptin to reach Cmax (Tmax) was increased by approximately 0.5 hours with food compared with the fasted state.
Čas, v katerem je saksagliptin dosegel Cmax (tmax), se je ob zaužitju s hrano podaljšal za približno 0,5 ure v primerjavi s stanjem na tešče.
A small decrease in absolute lymphocyte count was observed.
Opazili so majhno zmanjšanje absolutnega števila limfocitov.
Stop taking Komboglyze for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal.
Za kratek čas prenehajte jemati zdravilo Komboglyze, če imate stanje, ki je lahko povezano z dehidracijo (znatna izguba telesnih tekočin), kot je hudo bruhanje, driska, zvišana telesna temperatura, izpostavljenost vročini ali če pijete manj tekočine, kot običajno.
Food decreases the extent and slightly delays the absorption of metformin.
Hrana zmanjša absorpcijo metformina in jo rahlo upočasni.
Saxagliptin or metformin has a negligible influence on the ability to drive and use machines.
Saksagliptin ali metformin imata zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Therefore, in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering, ulceration or rash, is recommended.
Zato je v skladu z rutinsko oskrbo sladkornega bolnika priporočljivo spremljanje glede kožnih sprememb, npr. mehurjev, razjed ali izpuščaja.
In rabbits, co-administration was poorly tolerated in many mothers, resulting in death, moribundity or abortion.
Pri kuncih so številne samice-matere sočasno uporabo slabo prenašale in je povzročila smrt, moribundnost ali splav.
Saxagliptin was not genotoxic in a conventional battery of genotoxicity studies in vitro and in vivo.
Saksagliptin ni bil genotoksičen v konvencionalni skupini študij genotoksičnosti in vitro in in vivo.
Avoid excessive alcohol intake while taking Komboglyze since this may increase the risk of lactic acidosis (see “Warnings and precautions”).
Med jemanjem zdravila Komboglyze ne uživajte čezmernih količin alkohola, saj lahko to poveča tveganje za laktacidozo (glejte poglavje "Opozorila in previdnostni ukrepi").
What you need to know before you take Komboglyze
Kaj morate vedeti, preden boste vzeli zdravilo Komboglyze
You may need more frequent blood glucose and kidney function tests, or your doctor may adjust the dosage of Komboglyze.
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic, zdravnik pa bo morda moral prilagoditi odmerek zdravila Komboglyze.
Caution is warranted if this medicinal product is used in patients who have known risk factors for hospitalisation for heart failure, such as a history of heart failure or moderate to severe renal impairment.
Previdnost je potrebna, če je to zdravilo uporabljeno pri bolnikih z znanimi dejavniki tveganja za hospitalizacijo zaradi srčnega popuščanja, npr. pri bolnikih z anamnezo srčnega popuščanja ali z zmerno do hudo okvaro ledvic.
• in patients inadequately controlled on their maximally tolerated dose of metformin alone
• ki je nezadostno urejena z največjim toleriranim odmerkom samega metformina;
Adjusted mean change from baseline adjusted for baseline value (ANCOVA).
Korigirana povprečna sprememba od izhodišča, korigirana za izhodiščno vrednosti (ANCOVA).
At the usual metformin doses and dosing schedules, steady state plasma concentrations are reached within 24-48 h and are generally less than 1 μg/mL.
Ob običajnih odmerkih in odmernih shemah metformina je koncentracija v stanju dinamičnega ravnovesja v plazmi dosežena v 24 do 48 urah in je na splošno manjša od 1 µg/ml.
• flatulence
• flatulenca
Decrease in body weight in the treatment groups given saxagliptin in combination with metformin was similar to that in the groups given metformin alone.
Zmanjšanje telesne mase v terapevtskih skupinah, ki so dobivale saksagliptin v kombinaciji z metforminom, je bilo podobno kot v skupinah, ki so dobivale samo metformin.
In case of dehydration (severe diarrhoea or vomiting, fever, heat, reduced fluid intake), Komboglyze should be temporarily discontinued and contact with a health care professional is recommended.
V primeru dehidracije (huda driska ali bruhanje, zvišana telesna temperatura ali zmanjšan vnos tekočine) je treba jemanje zdravila Komboglyze začasno prekiniti; priporoča se posvet z zdravstvenim delavcem.
In addition, patients should be alerted to the risk of hypoglycaemia when Komboglyze is used in combination with other antidiabetic medicinal products known to cause hypoglycaemia (e.g. insulin, sulphonylureas).
Poleg tega je treba bolnike opozoriti na tveganje za hipoglikemijo, če je zdravilo Komboglyze uporabljeno v kombinaciji z drugimi antidiabetičnimi zdravili, za katere je znano, da povzročajo hipoglikemijo (npr. insulin, sulfonilsečnine).
The other ingredients (excipients) are:
Druge sestavine zdravila (pomožne snovi) so:
Renal function As metformin is excreted by the kidney, renal function should be assessed: - Before initiation of treatment and regularly thereafter (see sections 4.2, 4.8, 5.1 and 5.2).
Delovanje ledvic Ker se metformin izloča skozi ledvice, je treba oceniti delovanje ledvic: - Pred uvedbo zdravila in nato redno (glejte poglavja 4.2, 4.8, 5.1 in 5.2).
Includes saxagliptin in add-on to metformin and initial combination with metformin.
Vključuje saksagliptin kot dodatek metforminu in začetno kombinacijo z metforminom.
There have been no formal interaction studies for Komboglyze.
Z zdravilom Komboglyze niso izvedli formalnih študij medsebojnega delovanja.
Komboglyze with alcohol
Zdravilo Komboglyze skupaj z alkoholom
Table 4 The frequency of metformin adverse reactions identified from clinical trial and postmarketing data
Preglednica 4 Pogostnost neželenih učinkov metformina, ugotovljenih v kliničnih preskušanjih in iz obdobja trženja
If you forget to take Komboglyze
Če ste pozabili vzeti zdravilo Komboglyze
What Komboglyze is and what it is used for What you need to know before you take Komboglyze How to take Komboglyze
Kaj je zdravilo Komboglyze in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Komboglyze Kako jemati zdravilo Komboglyze Možni neželeni učinki
This is because metformin passes into human milk in small amounts.
Metformin namreč v majhni količini prehaja v materino mleko.
The rise in insulin from pancreatic beta-cells and the decrease in glucagon from pancreatic alpha-cells were associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal.
Povečanje insulina iz pankreatičnih celic beta in zmanjšanje glukagona iz pankreatičnih celic alfa sta bili povezani z manjšo koncentracijo glukoze na tešče in manjšim porastom glukoze po peroralni obremenitvi z glukozo ali po obroku.
Following administration of a dose of 850 mg, a 40% lower plasma peak concentration, a 25% decrease in AUC and a 35 min prolongation of time to peak plasma concentration was observed.
Po uporabi 850 mg odmerka so ugotovili 40 % manjšo največjo koncentracijo v plazmi, 25 % zmanjšanje AUC in 35-minutno podaljšanje časa do največje koncentracije v plazmi.
• redness of the skin (rash) or itching.
• pordelost kože (izpuščaj) ali srbenje.
• nausea, vomiting
• siljenje na bruhanje, bruhanje
The pharmacokinetics of saxagliptin and its major metabolite were similar in healthy subjects and in patients with type 2 diabetes.
Farmakokinetika saksagliptina in njegovega glavnega presnovka sta bili pri zdravih preiskovancih in bolnikih s sladkorno boleznijo tipa 2 podobni.
GENERATION was a 52-week glycaemic control study in 720 elderly patients, the mean age was 72.6 years; 433 subjects (60.1%) were < 75 years of age, and 287 subjects (39.9%) were ≥ 75 years of age.
Študija GENERATION je bila 52-tedenska študija urejenosti glikemije pri 720 starejših bolnikih, povprečno starih 72,6 let; 433 bolnikov (60,1 %) je bilo starih < 75 let, 281 bolnikov (39,9 %) pa je bilo starih ≥ 75 let.
The clinical significance of this decrease in lymphocyte count relative to placebo is not known.
Klinični pomen zmanjšanja števila limfocitov, v primerjavi s placebom, ni znan.
Another secondary endpoint, all-cause mortality, occurred at a rate of 5.1% in the saxagliptin group and 4.6% in the placebo group (see Table 7).
Drug sekundarni opazovani dogodek, umrljivost zaradi vseh vzrokov, se je v skupini s saksagliptinom pojavil v 5,1 % in v skupini s placebom v 4,6 % (glejte preglednico 7).
If you have or have had a disease of the pancreas;
če imate ali ste kdaj imeli bolezen trebušne slinavke (pankreasa).
For the major metabolite, renal clearance values were comparable to estimated glomerular filtration rate.
Za glavni presnovek so bile vrednosti ledvičnega očistka primerljive ocenjeni hitrosti glomerularne filtracije.
If this happens you must stop taking Komboglyze and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma.
V tem primeru morate prenehati jemati zdravilo Komboglyze in se takoj obrniti na zdravnika ali najbližjo bolnišnico, saj lahko laktacidoza vodi v komo.
• muscle pain (myalgia)
• bolečina v mišici (mialgija)
Pack sizes of 14, 28, 56 and 60 film-coated tablets in non-perforated blisters.
Velikosti pakiranj s 14, 28, 56 in 60 filmsko obloženimi tabletami v neperforiranih pretisnih omotih.
Use with medicinal products known to cause hypoglycaemia Insulin and sulphonylureas are known to cause hypoglycaemia.
Uporaba z zdravili za katera je znano, da povzročajo hipoglikemijo Znano je, da insulin in sulfonilsečnine povzročajo hipoglikemijo.
Saxagliptin also resulted in a significantly lower proportion of patients with hypoglycaemia, 3% (19 events in 13 subjects) vs. 36.3% (750 events in 156 patients) for glipizide.
Saksagliptin je bil povezan tudi z značilno manjšim deležem hipoglikemij (3 %; 19 dogodkov pri 13 osebah) kot glipizid (36,3 %; 750 dogodkov pri 156 bolnikih).
Metformin is a biguanide with antihyperglycaemic effects, lowering both basal and postprandial plasma glucose.
Metformin je bigvanid z antihiperglikemičnimi učinki, ki zmanjšuje bazalno in postprandialno glukozo v plazmi.
The SAVOR trial included 8240 patients treated with saxagliptin 5 mg or 2.5 mg once daily and 8173 patients on placebo.
Preskušanje SAVOR je zajelo 8240 bolnikov, zdravljenih z 2,5 mg ali 5 mg saksagliptina enkrat na dan, in 8173 bolnikov, ki so prejemali placebo.
Therapy may be restarted no earlier than 48 hours following surgery or resumption of oral nutrition provided that renal function has been re-evaluated and found to be stable.
Zdravljenje se sme ponovno uvesti najmanj 48 ur po kirurškem posegu ali začetku peroralnega prehranjevanja, če je bilo delovanje ledvic ponovno ovrednoteno in ocenjeno kot stabilno.
What Komboglyze looks like and contents of the pack
Izgled zdravila Komboglyze in vsebina pakiranja
You should call your doctor if you experience the following side effect: • severe joint pain.
Posvetujte se z zdravnikom, če se vam pojavijo naslednji neželeni učinki: • hude bolečine v sklepih.
Stop taking Komboglyze and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma.
Takoj prenehajte jemati zdravilo Komboglyzein se obrnite na zdravnika ali najbližjo bolnišnico, če se pojavijo nekateri od simptomov laktacidoze, saj lahko to stanje vodi v komo.
Do not use this medicine if the package is damaged or shows signs of tampering.
Ne uporabljajte tega zdravila, če opazite, da je pakiranje poškodovano ali ima vidne znake, da ga je že kdo odpiral.
If you need to have an injection of contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Komboglyze before or at the time of the injection.
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Komboglyze.
During postmarketing experience, including spontaneous reports and clinical trials, the following adverse reactions have been reported with the use of saxagliptin: serious hypersensitivity reactions, including anaphylactic reaction, anaphylactic shock, and angioedema.
Iz izkušenj iz obdobja trženja, vključno s spontanimi poročili in kliničnimi preskušanji, so glede uporabe saksagliptina poročali o naslednjih neželenih učinkih: resnih preobčutljivostnih reakcijah, vključno z anafilaktično reakcijo, anafilaktičnim šokom in angioedemu.
However, among surviving mothers with evaluable litters, maternal toxicity was limited to marginal reductions in body weight over the course of gestation days 21 to 29; and associated developmental toxicity in these litters was limited to foetal body weight decrements of 7%, and a low incidence of delayed ossification of the foetal hyoid.
Toda med preživelimi samicami z ocenljivimi legli, je bila maternalna toksičnost omejena na mejno zmanjšanje telesne mase od 21. do 29. dne gestacije; spremljajoči razvojni toksični učinki pri teh leglih so bili omejeni na 7 % zmanjšanje telesne mase plodov in majhno incidenco zapoznele osifikacije plodove hioidne kosti.
Komboglyze should be given twice daily with meals to reduce the gastrointestinal adverse reactions associated with metformin.
Zdravilo Komboglyze je treba uporabljati dvakrat na dan in s hrano, da bi zmanjšali z metforminom povezane neželene učinke na prebavilih.
If a serious hypersensitivity reaction to saxagliptin is suspected, discontinue this medicinal product, assess for other potential causes for the event, and institute alternative treatment for diabetes (see sections 4.3 and 4.8).
Če se pojavi sum na resno preobčutljivostno reakcijo, je potrebno prekiniti zdravljenje s tem zdravilom, preučiti morebitne druge vzroke za dogodek, in uvesti drugo zdravljenje za sladkorno bolezen (glejte poglavji 4.3 in 4.8).
Hypoglycaemia may affect your ability to drive and use machines or work with safe foothold and there is a risk of hypoglycaemia when taking this medicine in combination with medicines known to cause hypoglycaemia such as insulin and sulphonylureas.
Hipoglikemija lahko poslabša vašo sposobnost za upravljanje vozil in strojev ter za dela z varno oporo; tveganje za hipoglikemijo obstaja, če to zdravilo jemljete v kombinaciji z zdravili, za katera je znano, da povzročajo hipoglikemijo (npr. insulin in sulfonilsečnine).
Primary composite endpoint: MACE Secondary composite endpoint: MACE plus All-cause mortality
Sekundarni sestavljeni opazovani dogodek: MACE plus Umrljivost zaradi vseh vzrokov
Administration with food (a high-fat meal) resulted in no change in saxagliptin Cmax and a 27% increase in AUC compared with the fasted state.
Uporaba s hrano (zelo masten obrok) ni spremenila Cmax saksagliptina, njegovo AUC pa je, v primerjavi z uporabo na tešče, povečala za 27 %.
• Komboglyze is available in aluminium foil blister.
• Zdravilo Komboglyze je na voljo v pretisnem omotu iz aluminijaste folije.
Pharmacotherapeutic group: Drugs used in diabetes, Combinations of oral blood glucose lowering drugs, ATC code: A10BD10.
Farmakoterapevtska skupina: Zdravila za zdravljenje diabetesa, kombinacije peroralnih antidiabetikov Oznaka ATC: A10BD10
The major metabolite of saxagliptin is also a selective, reversible, competitive DPP4 inhibitor, half as potent as saxagliptin.
Tudi glavni presnovek saksagliptina je selektiven, reverzibilen, kompetitiven zaviralec DPP4, pol tako močan kot saksagliptin.
In postmarketing experience of saxagliptin, there have been spontaneously reported adverse reactions of acute pancreatitis.
Iz izkušenj v obdobju trženja saksagliptina so spontano poročali o neželenem učinku akutnem pankreatitisu.
SAVOR trial results
Rezultati preskušanja SAVOR
This medicineshould not be used to treat this condition;
Tega zdravila se ne sme uporabljati za zdravljenje te bolezni.
Immune system disorders Hypersensitivity reactions
Bolezni imunskega sistema preobčutljivostne reakcije
In patients with type 2 diabetes, administration of saxagliptin led to inhibition of DPP4 enzyme activity for a 24-hour period.
Pri bolnikih s sladkorno boleznijo tipa 2 je uporaba saksagliptina zavrla delovanje encima DPP4 za 24 ur.
The increased risk of overall and major hypoglycaemia was primarily observed in subjects with A1C < 7% at baseline.
Večje tveganje za vse hipoglikemije in hujše hipoglikemije so ugotovili predvsem med preiskovanci, ki so imeli izhodiščno A1c < 7 %.
Alcohol intoxication is associated with an increased risk of lactic acidosis, particularly in the case of fasting, malnutrition or hepatic impairment due to the metformin active substance of Komboglyze (see section 4.4).
Zastrupitev z alkoholom je povezana s povečanim tveganjem za laktacidozo, zlasti ob postenju, podhranjenosti ali okvari jeter, zaradi vsebnosti učinkovine metformina v zdravilu Komboglyze (glejte poglavje 4.4).
Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, ACE inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics.
Nekatera zdravila lahko škodljivo vplivajo na delovanje ledvic, kar lahko poveča tveganje za laktacidozo, npr. NSAID, vključno s selektivnimi zaviralci ciklooksigenaze (COX) II, zaviralci ACE, antagonisti receptorjev angiotenzina II in diuretiki, zlasti diuretiki Henlejeve zanke.
The results of bioequivalence studies in healthy subjects demonstrated that Komboglyze combination tablets are bioequivalent to co-administration of corresponding doses of saxagliptin and metformin hydrochloride as individual tablets.
Rezultati bioekvivalenčnih študij pri zdravih osebah so pokazali, da je kombinacija učinkovin v tableti Komboglyze bioekvivalentna sočasni uporabi ustreznih odmerkov saksagliptina in metforminijevega klorida v ločenih tabletah.
Side effects seen when taking saxagliptin alone: Common
Neželeni učinki, ki so jih zabeležili med jemanjem samega saksagliptina: Pogosti
In addition, saxagliptin did not meaningfully alter the pharmacokinetics of metformin, glibenclamide, pioglitazone, digoxin, simvastatin, the active components of a combined oral contraceptive (ethinyl estradiol and norgestimate), diltiazem or ketoconazole.
Poleg tega saksagliptin ni pomembno spremenil farmakokinetike metformina, glibenklamida, pioglitazona, digoksina, simvastatina, učinkovin v kombiniranih peroralnih kontraceptivih (etinilestradiola in norgestimata), diltiazema ali ketokonazola.
The primary safety (noninferiority) and efficacy (superiority) endpoint was a composite endpoint consisting of the time-to-first occurrence of any of the following major adverse CV events (MACE): CV death, nonfatal myocardial infarction, or nonfatal ischaemic stroke.
Primarni opazovani dogodek varnosti (neinferiornosti) in učinkovitosti (superiornosti) je bil sestavljen opazovani dogodek, ki je obsegal čas do prvega pojava katerega od naslednjih hudih neželenih kardiovaskularnih dogodkov: kardiovaskularne smrti, miokardnega infarkta brez smrtnega izida ali možganske kapi brez smrtnega izida.
Concomitant use not recommended
Kombinacije, ki niso priporočljive
Table 5 Key efficacy results in placebo-controlled, combination therapy studies of saxagliptin and metformin
Preglednica 5 Ključni rezultati o učinkovitosti v s placebom kontrolirani študiji kombiniranega zdravljenja s saksagliptinom in metforminom
No data are available with regard to overdose of Komboglyze.
Podatkov o prevelikem odmerjanju z zdravilom Komboglyze ni.
After an oral glucose load, this DPP4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), decreased glucagon concentrations and increased glucose-dependent beta-cell responsiveness, which resulted in higher insulin and C-peptide concentrations.
Po peroralni obremenitvi z glukozo je to zavrtje DPP4 povzročilo 2- do 3-kratno povečanje koncentracije aktivnih inkretinskih hormonov v obtoku (vključno z glukagonu podobnim peptidom-1 (GLP-1) in od glukoze odvisnim insulinotropnim polipeptidom (GIP)), zmanjšalo koncentracijo glukagona in povečalo od glukoze odvisno odzivnost celic beta, zaradi česar sta se povečali koncentracija insulina in C-peptida.
Postmarketing experience from clinical trials and spontaneous reports Table 3 shows additional adverse reactions which have been reported in postmarketing experience with saxagliptin.
Izkušnje iz kliničnih preskušanj in spontana poročila iz obdobja trženja Preglednica 3 prikazuje dodatne neželene učinke o katerih so poročali iz izkušenj v obdobju trženja saksagliptina.
In the confirmatory full analysis set, mean reductions were -0.4% and -0.6% respectively for saxagliptin and sitagliptin, with median reductions of -0.5% for both groups.
Potrditvena analiza polnega nabora je pokazala za saksagliptin povprečno zmanjšanje za -0,4 % in za sitagliptin za -0,6 %; mediano zmanjšanje je bilo v obeh skupinah -0,5 %.
• in patients already being treated with the combination of saxagliptin and metformin as separate tablets.
• pri bolnikih, ki že prejemajo kombinacijo saksagliptina in metformina v ločenih tabletah.
Studies in animals have shown excretion of both saxagliptin and/or metabolite and metformin in milk.
Študije na živalih so pokazale, da se saksagliptin in/ali njegov presnovek in metformin izločajo v mleko.
The effect on HbA1c observed at Week 24 was sustained at Week 52.
Učinek na HbA1c, opažen po 24 tednih, se je ohranil tudi po 52 tednih.
- In patients with moderate renal impairment that have GFR ≥ 30 to < 45 mL/min, in the absence of other conditions that may increase the risk of lactic acidosis, the dose is 2.5 mg/1000 mg or 2.5 mg/850 mg once daily.
- Pri bolnikih z zmerno okvaro ledvic, ki imajo GFR od ≥ 30 do <45 ml/min, v odsotnosti drugih stanj, ki bi povečevala tveganje za laktacidozo, je odmerek 2,5 mg/1000 mg ali 2,5 mg/850 mg enkrat na dan. Tem bolnikom ni priporočljivo uvesti zdravila.
Reductions in HbA1c from baseline to Week 24 were observed in all evaluated subgroups defined by baseline HbA1c, with greater reductions observed in patients with a baseline HbA1c ≥ 10% (see Table 5).
Zmanjšanje HbA1c od izhodišča do 24. tedna so opazili v vseh ocenjenih podskupinah, določenih glede na izhodiščni HbA1c; večja zmanjšanja so ugotovili pri bolnikih, ki so imeli izhodiščni HbA1c ≥ 10 % (glejte preglednico 3).
The decreases in lymphocyte count were not associated with clinically relevant adverse reactions.
Zmanjšanega števila limfocitov niso spremljali klinično pomembni neželeni učinki.
If you need to have major surgery, you must stop taking Komboglyze during and for some time after the procedure.
Če morate na večji kirurški poseg, morate v času posega in še nekaj časa po tem prenehati z jemanjem zdravila Komboglyze.
The biotransformation of saxagliptin is primarily mediated by cytochrome P450 3A4/5 (CYP3A4/5).
Biotransformacija saksagliptina poteka predvsem prek citokroma P450 3A4/5 (CYP3A4/5).
Frequency of adverse reactions by treatment regimen
Pogostnost neželenih učinkov po shemi zdravljenja
Placebo-corrected mean change in HbA1c (%) (95% CI)
Na placebo korigirana povprečna sprememba HbA1c (%) (95 % IZ)
• infection of the upper airways
• okužba zgornjih dihal
What Komboglyze is used for This medicine is used to treat a type of diabetes called ‘type 2 diabetes'.
To zdravilo uporabljamo za zdravljenje vrste sladkorne bolezni, imenovane "sladkorna bolezen tipa 2".